常见皮肤药物反应

Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ. 2003;327:1222-1225.

• 摘要

Gell PG, Coombs RRA, eds. Clinical aspects of immunology. 1st ed. Oxford: Blackwell; 1963.

Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256:3358-3363.

• 摘要

Kuokkanen K. Drug eruptions: a series of 464 cases in the Department of Dermatology, University of Turku, Finland, during 1966-1970. Acta Allergol. 1972;27:407-438.

• 摘要

Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28:851-870.

• 摘要

Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.

• 摘要

Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.

• 全文
• 摘要

Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med. 2009;102:186-194.

• 摘要

National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. September 2014. http://www.nice.org.uk (last accessed 15 September 2016).

• 全文

1.  Aronson JK. Adverse drug reactions: history, terminology, classification, causality, frequency, preventability. In: Talbot J, Aronson JK, eds. Stephens’ detection and evaluation of adverse drug reactions: principles and practice. 6th ed. Oxford: Wiley-Blackwell; 2011.

2.  Health Canada. Adverse reaction information. October 2012. http://www.hc-sc.gc.ca (last accessed 15 September 2016).

• 全文

3.  Warrington R, Silviu-Dan F. Drug allergy. Allergy Asthma Clin Immunol. 2011;7(suppl 1):S10.

• 全文
• 摘要

4.  Gruchalla RS. Drug allergy. J Allergy Clin Immunol. 2003;111(suppl 2):S548-S559.

• 摘要

5.  Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140:795-801.

• 摘要

6.  Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1977:10.

7.  Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ. 2003;327:1222-1225.

• 摘要

8.  Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.

• 全文
• 摘要

9.  Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68:1781-1791.

• 全文

10.  Gell PG, Coombs RRA, eds. Clinical aspects of immunology. 1st ed. Oxford: Blackwell; 1963.

11.  Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832-836.

• 摘要

12.  Gonzalo-Garijo MA, de Argila D. Erythroderma due to aztreonam and clindamycin. J Investig Allergol Clin Immunol. 2006;16:210-211.

• 全文
• 摘要

13.  Akcam M, Artan R, Akcam FZ, et al. Nail discoloration induced by doxycycline. Pediatr Infect Dis J. 2005;24:845-846.

• 摘要

14.  Rogers KC, Wolfe DA. Amiodarone-induced blue-gray syndrome. Ann Pharmacother. 2000;34:1075.

• 摘要

15.  Jia Y, Lacouture ME, Su X, et al. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol. 2009;7:211-217.

• 摘要

16.  Drucker AM, Wu S, Busam KJ, et al. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. Eur J Haematol. 2013;90:142-150.

• 摘要

17.  Rosen AC, Wu S, Damse A, et al. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97:1125-1133.

• 全文
• 摘要

18.  Fischer A, Wu S, Ho AL, et al. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2013;31:787-797.

• 摘要

19.  Chu D, Lacouture ME, Weiner E, et al. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer. 2009;7:11-19.

• 摘要

20.  Minkis K, Garden BC, Wu S, et al. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69:e121-e128.

• 摘要

21.  Drucker AM, Wu S, Dang CT, et al. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat. 2012;135:347-354.

• 摘要

22.  Fiorino G, Allez M, Malesci A, et al. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:921-927.

• 全文
• 摘要

23.  Su X, Lacouture ME, Jia Y, et al. Risk of high-grade skin rash in cancer patients treated with cetuximab: an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology. 2009;77:124-133.

• 摘要

24.  Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256:3358-3363.

• 摘要

25.  Kuokkanen K. Drug eruptions: a series of 464 cases in the Department of Dermatology, University of Turku, Finland, during 1966-1970. Acta Allergol. 1972;27:407-438.

• 摘要

26.  Hernández-Salazar A, Rosales SP, Rangel-Frausto S, et al. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res. 2006;37:899-902.

• 摘要

27.  Castro-Pastrana LI, Ghannadan R, Rieder MJ, et al. Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). J Popul Ther Clin Pharmacol. 2011;18:e106-e120.

• 摘要

28.  Lecluse LL, Dowlatshahi EA, Limpens CE, et al. Etanercept: an overview of dermatologic adverse events. Arch Dermatol. 2011;147:79-94.

• 摘要

29.  Goh CL. Nonoccupational contact dermatitis. Clin Dermatol. 1998;16:119-127.

• 摘要

30.  Yip VL, Marson AG, Jorgensen AL, et al. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther. 2012;92:757-765.

• 摘要

31.  Van den Haute V, Antoine JL, Lachapelle JM. Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples. Dermatologica. 1989;179:10-13.

• 摘要

32.  Hughes CA, Foisy MM, Dewhurst N, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother. 2008;42:387-396.

• 摘要

33.  Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics. 2008;9:207-214.

• 摘要

34.  Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156:609-611.

• 摘要

35.  Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol. 2009;9:322-328.

• 摘要

36.  Ozkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges. 2008;6:181-188.

• 摘要

37.  Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124:588-597.

• 摘要

38.  Lee A, Thomson J. Drug-induced skin reactions. In: Lee A, ed. Adverse drug reactions. 2nd ed. London: Pharmaceutical Press; 2006:125-156.

• 全文

39.  Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28:851-870.

• 摘要

40.  Wang L, Cheng L, Yuan Q, et al. Adverse drug reactions of Shuanghuanglian injection: a systematic review of public literatures. J Evid Based Med. 2010;3:18-26.

• 摘要

41.  Polak ME, Belgi G, McGuire C, et al. In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. Br J Dermatol. 2013;168:539-549.

• 摘要

42.  Haw WY, Polak ME, McGuire C, et al. In vitro rapid diagnostic tests for severe drug hypersensitivity reactions in children. Ann Allergy Asthma Immunol. 2016;117:61-66.

• 摘要

43.  Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.

• 摘要

44.  Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.

• 全文
• 摘要

45.  Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med. 2009;102:186-194.

• 摘要

46.  National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. September 2014. http://www.nice.org.uk (last accessed 15 September 2016).

• 全文

47.  Lee AY. Fixed drug eruptions: incidence, recognition, and avoidance. Am J Clin Dermatol. 2000;1:277-285.

• 摘要

48.  Resuscitation Council (UK). Emergency treatment of anaphylactic reactions: guidelines for healthcare providers. July 2012. http://www.resus.org.uk/ (last accessed 15 September 2016).

• 全文

49.  Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115:341-84.

• 摘要

50.  Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149-153.

• 全文
• 摘要

51.  Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174:1194-1227.

• 全文
• 摘要

52.  Mydlarski PR, Ho V, Shear NH. Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. J Cutan Med Surg. 2006;10:205-221.

• 摘要

53.  Enk A; European Dermatology Forum Guideline Subcommittee. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol. 2009;19:90-98.

• 摘要

54.  Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007;119:1497-1503.

• 摘要

55.  Simons FE, Ardusso LR, Bilò MB, et al; World Allergy Organization. 2012 update: World Allergy Organization guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol. 2012;12:389-399.

• 摘要

56.  Simons FE, Ardusso LR, Dimov V, et al; World Allergy Organization. World Allergy Organization anaphylaxis guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol. 2013;162:193-204.

• 全文
• 摘要